American International Group Inc. decreased its position in shares of Emergent Biosolutions, Inc. (NYSE:EBS) by 17.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 20,006 shares of the biopharmaceutical company’s stock after selling 4,104 shares during the period. American International Group Inc.’s holdings in Emergent Biosolutions were worth $581,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of EBS. Comerica Bank boosted its position in shares of Emergent Biosolutions by 0.9% in the fourth quarter. Comerica Bank now owns 60,921 shares of the biopharmaceutical company’s stock worth $1,868,000 after buying an additional 535 shares during the period. FMR LLC boosted its position in shares of Emergent Biosolutions by 39.7% in the fourth quarter. FMR LLC now owns 288,348 shares of the biopharmaceutical company’s stock worth $9,469,000 after buying an additional 81,898 shares during the period. New York State Teachers Retirement System boosted its position in shares of Emergent Biosolutions by 1.7% in the fourth quarter. New York State Teachers Retirement System now owns 35,955 shares of the biopharmaceutical company’s stock worth $1,181,000 after buying an additional 600 shares during the period. Envestnet Asset Management Inc. raised its stake in Emergent Biosolutions by 29.6% in the fourth quarter. Envestnet Asset Management Inc. now owns 4,866 shares of the biopharmaceutical company’s stock worth $159,000 after buying an additional 1,110 shares in the last quarter. Finally, A.R.T. Advisors LLC purchased a new stake in Emergent Biosolutions during the fourth quarter worth $410,000. 85.41% of the stock is owned by institutional investors.

Shares of Emergent Biosolutions, Inc. (NYSE EBS) traded down 0.98% during mid-day trading on Thursday, hitting $35.22. 326,290 shares of the stock were exchanged. Emergent Biosolutions, Inc. has a 52-week low of $24.47 and a 52-week high of $36.81. The stock has a 50-day moving average price of $34.24 and a 200 day moving average price of $31.22. The firm has a market cap of $1.44 billion, a price-to-earnings ratio of 26.89 and a beta of 1.22.

Emergent Biosolutions (NYSE:EBS) last issued its earnings results on Thursday, May 4th. The biopharmaceutical company reported $0.23 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.31 by $0.08. Emergent Biosolutions had a net margin of 10.36% and a return on equity of 11.92%. The firm had revenue of $116.90 million during the quarter, compared to analyst estimates of $121.30 million. During the same quarter last year, the business posted $0.16 earnings per share. The company’s revenue for the quarter was up 13.5% on a year-over-year basis. On average, equities research analysts expect that Emergent Biosolutions, Inc. will post $1.58 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This article was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/08/03/emergent-biosolutions-inc-ebs-stake-lowered-by-american-international-group-inc-updated-updated-updated.html.

A number of analysts have weighed in on EBS shares. BidaskClub upgraded shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. Zacks Investment Research lowered shares of Emergent Biosolutions from a “hold” rating to a “sell” rating in a research note on Monday, July 17th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $39.25.

In related news, Chairman Fuad El-Hibri sold 25,000 shares of the firm’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $35.50, for a total value of $887,500.00. Following the completion of the sale, the chairman now directly owns 1,655,216 shares in the company, valued at approximately $58,760,168. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 16.50% of the company’s stock.

About Emergent Biosolutions

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Stock Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related stocks with our FREE daily email newsletter.